Abstract
Interleukin-1 beta (IL1) and tumor necrosis factor alpha (TNF) promote non-rapid eye movement sleep under physiological and inflammatory conditions. Additional cytokines are also likely involved but evidence is insufficient to conclude that they are sleep regulatory substances. Many of the symptoms induced by sleep loss, e.g. sleepiness, fatigue, poor cognition, enhanced sensitivity to pain, can be elicited by injection of exogenous IL1 or TNF. We propose that ATP, released during neurotransmission, acting via purine P2 receptors on glia releases IL1 and TNF. This mechanism may provide the means by which the brain keeps track of prior usage history. IL1 and TNF in turn act on neurons to change their intrinsic properties and thereby change input-output properties (i.e. state shift) of the local network involved. Direct evidence indicates that cortical columns oscillate between states, one of which shares properties with organism sleep. We conclude that sleep is a local use-dependent process influenced by cytokines and their effector molecules such as nitric oxide, prostaglandins and adenosine.
Keywords: Local sleep, interleukin, TNF, neurotrophin, adenosine, purine P2 receptors
Current Pharmaceutical Design
Title: The Role of Cytokines in Sleep Regulation
Volume: 14 Issue: 32
Author(s): James M. Krueger
Affiliation:
Keywords: Local sleep, interleukin, TNF, neurotrophin, adenosine, purine P2 receptors
Abstract: Interleukin-1 beta (IL1) and tumor necrosis factor alpha (TNF) promote non-rapid eye movement sleep under physiological and inflammatory conditions. Additional cytokines are also likely involved but evidence is insufficient to conclude that they are sleep regulatory substances. Many of the symptoms induced by sleep loss, e.g. sleepiness, fatigue, poor cognition, enhanced sensitivity to pain, can be elicited by injection of exogenous IL1 or TNF. We propose that ATP, released during neurotransmission, acting via purine P2 receptors on glia releases IL1 and TNF. This mechanism may provide the means by which the brain keeps track of prior usage history. IL1 and TNF in turn act on neurons to change their intrinsic properties and thereby change input-output properties (i.e. state shift) of the local network involved. Direct evidence indicates that cortical columns oscillate between states, one of which shares properties with organism sleep. We conclude that sleep is a local use-dependent process influenced by cytokines and their effector molecules such as nitric oxide, prostaglandins and adenosine.
Export Options
About this article
Cite this article as:
Krueger M. James, The Role of Cytokines in Sleep Regulation, Current Pharmaceutical Design 2008; 14 (32) . https://dx.doi.org/10.2174/138161208786549281
DOI https://dx.doi.org/10.2174/138161208786549281 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cognitive Functions under Anti-HER2 Targeted Therapy in Cancer Patients: A Scoping Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Cartilage Oligomeric Matrix Protein: Matricellular and Matricrine Signaling in Cardiovascular Homeostasis and Disease
Current Vascular Pharmacology Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
Current Drug Metabolism Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Current Pharmaceutical Design Transactivation of EGFR by G Protein-Coupled Receptor in the Pathophysiology of Intimal Hyperplasia
Current Vascular Pharmacology Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome
Current Pharmaceutical Design Arterial Mechanics and Dynamics in Hypertension
Current Hypertension Reviews Potential Application of Induced Pluripotent Stem Cells in Cell Replacement Therapy for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Lipid Nanocarriers and Molecular Targets for Malaria Chemotherapy
Current Drug Targets Epigenetic Modulation of Myocardial Angiogenic Balance: An Emerging Therapeutic Perspective for Adult Failing Heart
Current Angiogenesis (Discontinued) Telmisartan in the Management of Diabetic Nephropathy: A Contemporary View
Current Diabetes Reviews Human Urotensin II Promotes Hypertension and Atherosclerotic Cardiovascular Diseases
Current Medicinal Chemistry Natural Products from Plants as Drug Candidates and Lead Compounds Against Leishmaniasis and Trypanosomiasis
Current Medicinal Chemistry Targeting Triglyceride Metabolism for Colorectal Cancer Prevention and Therapy
Current Drug Targets Determinants of Perceived Severity of Hypertension and Drug-Compliance in Hypertensive Patients
Cardiovascular & Hematological Disorders-Drug Targets The Potential Roles of Gamma-Glutamyltransferase Activity in the Progression of Atherosclerosis and Cardiovascular Diseases
Vascular Disease Prevention (Discontinued) Recent Advances and Patents on Mechanical Circulatory Support Devices
Recent Patents on Biomedical Engineering (Discontinued) Halting Arterial Aging in Patients with Cardiovascular Disease: Hypolipidemic and Antihypertensive Therapy
Current Pharmaceutical Design Dietary Prevention of Coronary Heart Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Dietary Fish Oil Reduces Colon Cancer Risk
Current Organic Chemistry